Clinical Trial Update: Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating sargramostim for patients with chronic phase chronic myeloid leukemia who did not ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Leukemia | Phase 2 | Status: COMPLETED